Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
2024-03-27 11:24
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
2024-03-21 00:22
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
2023-12-29 12:33
Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair
2023-10-24 13:39
Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre
2023-10-10 13:54
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress
2023-08-28 11:08
Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
2023-07-27 10:57
Inclusion of Recbio In the MSCI China Small Cap Index
2023-05-17 14:01
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
2023-03-21 13:59
Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610
2023-02-13 15:02
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
2022-12-26 11:33
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
2022-12-19 13:53
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
2022-12-14 15:17
Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine
2022-11-21 16:07
Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV
2022-11-08 15:17
Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
2022-10-28 11:10
Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress
2022-08-29 13:08
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
2022-08-19 11:29
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine
2022-08-10 16:06
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
2022-08-03 13:09
1
2